3SOF

Quote from: hectorgr on March 21, 2014, 03:38:14 PM

Quote from: Terliso on March 21, 2014, 03:30:38 PM
GIGM and HEB is looking good too...

Scalped GIGM today and closed AKS. Watching BLDP probably buying on monday.

I'm in at GIGM @ 1.75 i'm in red right now, we will see next week. MNGA closed pretty solid it could gap up next week.

Quote from: Terliso on March 21, 2014, 03:30:38 PM
GIGM and HEB is looking good too...

Scalped GIGM today and closed AKS. Watching BLDP probably buying on monday.

GIGM and HEB is looking good too...

60 days, 15 min chart of MNGA

What a 26% quick profit on MNGA. I got in @ 1.86 before the breakout on second triangle and sold it at 2.35.... and now about to breakout for another 3rd triangle.

Oracle's Growth Will Return

Database giant Oracle (ORCL) disappointed investors on Tuesday with earnings and revenue that missed Street expectations. The stock was down more than 5% Tuesday after the close. And frustrated investors continue to wonder what else can go wrong with the enterprise software company.

Fiscal Third-Quarter Results

Oracle reported third quarter revenues of $9.3 billion, up 4% on the year before. But this wasn't enough to please investors. Analysts were looking for revenue of $9.36 billion. Oracle showed moderate strength in new software licenses and cloud software subscriptions. That business posted revenues of $2.4 billion, which was up 4% year over year. But that, too, was considered unimpressive.

Analysts like Daniel Ives of FBR Capital Markets wasn't impressed. Ives was looking for 7% growth in the cloud subscription business. He argued that the enterprise IT spending was strong enough to support this projection. Ives has been a notable critic of Oracle and believes that the company is being left behind by nimbler rivals like Salesforce.com (CRM) and Workday (WDAY).

But Ives overlooked some positives in Oracle's report. For instance, revenue from hardware systems products rose 8% to $725 million. This has been the first growth Oracle has experienced in that business in four years. This hardware growth accounts for 30% growth (on a constant currency basis) in the engineered server systems business. CEO Larry Ellison made certain that highlight this fact. He said:

"
"Our Engineered Systems business is growing rapidly for the same fundamental reason that our Cloud Applications business is growing rapidly. In both cases, customers want us to integrate the hardware and software and make it work together, so they don't have to."

Likewise, it's worth noting that Ellison has been extremely vocal about his intentions with Oracle. While the company has not demonstrated the growth that investors would like, management has been clear in its execution. Oracle is transitioning the business to stronger growth areas. What's more, Oracle's cloud software sales were actually up 25% year over year.

From an operational perspective, Oracle's results weren't as bad as the Street made them out to be. It's true that the company missed Wall Street's expectations for adjusted earnings per share. But GAAP earnings per share were up 8% to 56 cents. Likewise, non-GAAP earnings per share were up 5% to 68 cents per share.

Equally impressive is that fact that amid all of this anxiety about Oracle's future, it's encouraging that operating cash flow on a trailing twelve-month basis was up 10% to $15 billion. Again, where Oracle is perceived deficient in terms of revenue, the company has to forgotten how to make money. And when you consider that the revenue miss was by less than half a percentage point, there's clearly been an overreaction.

Looking ahead

For the current quarter, the company expects EPS (excluding items) to be in the range of 92 cents to 99 cents per share. Meanwhile, fourth-quarter revenue is projected to post year-over-year improvement of 3% to 7%. Analysts had modeled earnings of 95 cents and revenue of $11.5 billion, which suggests 5% growth.

Summary

The bullish case for Oracle is simple, as businesses strive for growth, the growth process will always place more demand on IT services. And as IT services get more complicated, it will require increased levels of expertise manage the enterprise. There is no other company more capable of delivering these services than Oracle.

All told, Oracle remains incredibly profitable. And the guidance for the final quarter is encouraging. As it stands, the stock looks incredibly cheap at 12-times forward earnings. On the basis improved cash flow and cloud-based software growth.

Oracle's Growth Will Return The Stock To $45 Per Share

Summary
• The bullish case for Oracle is simple, as businesses strive for growth, the growth process will always place more demand on IT services.
• From an operational perspective, Oracle's results weren't as bad as the Street made them out to be.
• Oracle remains incredibly profitable. And the guidance for the final quarter is encouraging.

Nice move with this baby...

Capstone isn't the only company set to profit from a booming energy market. These three stock have the potential to soar!

3 Stocks to Get on Your Watch List
I follow quite a lot of companies, so the usefulness of a watch list for me cannot be overstated. Without my watch list, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time came to choose which stock I'm buying or shorting next.

Capstone Turbine (NASDAQ: CPST)
Speaking of companies with highly volatile hit-and-miss potential, microturbine developer Capstone Turbine has to come to mind.

Shares of Capstone have been extremely volatile lately as anything resembling an alternative energy system has shot through the roof, from fuel-cell systems and ethanol producers to turbine and microturbine developers.

For Capstone, sales growth has been no issue. A week ago today Capstone secured an order for 50 Captsone C65 microturbines for oil and gas shale companies around the country, raising the total number of microturbines in use via its distributor Horizon Power Systems to 550. This order came just one week after securing a 2.6 MW order for two of Capstone's natural gas-powered microturbines from Regatta Solutions to be used in select California hospitals.

For more evidence we can turn to Capstone's third-quarter highlights, released in February, where it delivered record product revenue of $29.9 million, boosted its backlog 7% to $160.4 million, and, more importantly, produced a six percentage point improvement in gross margin to 20%.

Of course, the one monkey on Capstone's back has been that it still hasn't reached breakeven EBITDA despite its rapid top-line growth and cost controls. However, I suspect that could change in either the fourth or first quarter. Although Capstone's profits won't be much to admire for the next year or two, as long as it can continue to push margins healthfully in the 20%-25% range there's a strong possibility that it could head much higher over the long run. Yet again, this isn't a company for the faint of heart -- but it has all the makings of a solid growth candidate.


Novavax (NASDAQ: NVAX)
The biotechnology sector offers a number of wildcard, predominantly clinical-stage stocks that have the potential to double -- or halve -- their value depending on the outcome of a single trial or two. One company that tends to fit the mold here is Novavax.

Novavax is a developer of vaccines designed to treat infectious diseases around the globe. The good news for shareholders is that Novavax is already generating revenue thanks to an influenza vaccine research contract through BARDA, as well as a handful of collaborative partnerships. Although Novavax could be giving up some of its earning potential by partnering up, it can also spread its costs and risks, allowing it more opportunities to find that elusive home run in the biotech sector.

Currently, the most exciting research ongoing for Novavax is a phase 2 study for respiratory syncytial virus, or RSV, a disease that infects a patient's lungs and breathing passages. Most people can recover from RSV infection, but it can be more serious for infants and the elderly. According to the Centers for Disease Control and Prevention, nearly all children will be infected with RSV by age two, hence the need for additional research.

However, investors may also want to consider that even though Novavax's pipeline is still young and predominantly unproven, the company is being valued at more than $1 billion in terms of overall value. It's quite possible that Novavax will continue to burn cash for the foreseeable future as it invests in new development programs and moves forward with its ongoing phase 1 and phase 2 studies. This doesn't necessarily mean the company won't succeed, but it does put downside pressure on a company that has historically produced losses and had a cumulative free-cash outflow of $279 million over the past decade.

It also wouldn't take much for Novavax to be knocked off its high horse if one of its primary studies in either RSV or influenza didn't meet its goals. I would personally guess that more than half of Novavax's current value is built into the success of its RSV and influenza platform, so a disappointment in either of these studies could seriously affect Novavax's share price.

One way or another, this has big-move potential, and risk-friendly investors should have this company on their watch lists.


White Mountains Insurance Group (NYSE: WTM)
The property and casualty reinsurance business is far from glamorous, but if a relatively conservative and nearly rock-steady investment exists within the sector, I would contend that White Mountains Insurance just might be it.

White Mountains is engaged in underwriting property and casualty insurance, as well as reinsuring products through the U.S. As you might imagine, this means that White Mountains can occasionally find itself at the mercy of Mother Nature. Events like Hurricane Sandy have a way of heavily impacting P&C insurers and reinsurers, and there's unfortunately very little these companies can do to predict when and where a natural disaster will strike.

However, one aspect that does work in favor of P&C insurers is that they possess the pricing power to boost premiums for existing customers on an as needed basis to ensure that they cover the catastrophe costs. The past year was incredibly kind to White Mountains, with very little in the way of catastrophe losses. Overall, this helped push the company's book value higher by 9.5% to $642 per share. With White Mountains operating out of four primary segments it noted significant strength from OneBeacon Insurance (NYSE: OB  ) , whose book value grew 17.3% and whose combined ratio (a measure of margin for insurers) came in at a steady 92% compared to this quarter last year.

If I could nitpick one aspect of White Mountains' generally conservative approach to running a business, it's that its dividend is far too conservative. At just $1 annually, yielding less than 0.2%, dividend-seeking investors had best consider looking elsewhere.

That aside, White Mountains is currently valued at around 10% of its book value, which, historically, makes this a good time to buy. Don't expect miraculous growth with a diversified insurance company, but do expect to sleep well at night. I'd suggest giving White Mountains a closer inspection.

Add these companies to your personalized Watch List to keep up on the latest news with each company:
• Add Novavax to My Watch List.
• Add Capstone Turbine to My Watch List.
• Add White Mountains Insurance Group to My Watch List.

Capstone isn't the only company set to profit from a booming energy market. These three stock have the potential to soar!

3 Stocks to Get on Your Watch List
I follow quite a lot of companies, so the usefulness of a watch list for me cannot be overstated. Without my watch list, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time came to choose which stock I'm buying or shorting next.

Capstone Turbine (NASDAQ: CPST)
Speaking of companies with highly volatile hit-and-miss potential, microturbine developer Capstone Turbine has to come to mind.

Shares of Capstone have been extremely volatile lately as anything resembling an alternative energy system has shot through the roof, from fuel-cell systems and ethanol producers to turbine and microturbine developers.

For Capstone, sales growth has been no issue. A week ago today Capstone secured an order for 50 Captsone C65 microturbines for oil and gas shale companies around the country, raising the total number of microturbines in use via its distributor Horizon Power Systems to 550. This order came just one week after securing a 2.6 MW order for two of Capstone's natural gas-powered microturbines from Regatta Solutions to be used in select California hospitals.

For more evidence we can turn to Capstone's third-quarter highlights, released in February, where it delivered record product revenue of $29.9 million, boosted its backlog 7% to $160.4 million, and, more importantly, produced a six percentage point improvement in gross margin to 20%.

Of course, the one monkey on Capstone's back has been that it still hasn't reached breakeven EBITDA despite its rapid top-line growth and cost controls. However, I suspect that could change in either the fourth or first quarter. Although Capstone's profits won't be much to admire for the next year or two, as long as it can continue to push margins healthfully in the 20%-25% range there's a strong possibility that it could head much higher over the long run. Yet again, this isn't a company for the faint of heart -- but it has all the makings of a solid growth candidate.


Novavax (NASDAQ: NVAX)
The biotechnology sector offers a number of wildcard, predominantly clinical-stage stocks that have the potential to double -- or halve -- their value depending on the outcome of a single trial or two. One company that tends to fit the mold here is Novavax.

Novavax is a developer of vaccines designed to treat infectious diseases around the globe. The good news for shareholders is that Novavax is already generating revenue thanks to an influenza vaccine research contract through BARDA, as well as a handful of collaborative partnerships. Although Novavax could be giving up some of its earning potential by partnering up, it can also spread its costs and risks, allowing it more opportunities to find that elusive home run in the biotech sector.

Currently, the most exciting research ongoing for Novavax is a phase 2 study for respiratory syncytial virus, or RSV, a disease that infects a patient's lungs and breathing passages. Most people can recover from RSV infection, but it can be more serious for infants and the elderly. According to the Centers for Disease Control and Prevention, nearly all children will be infected with RSV by age two, hence the need for additional research.

However, investors may also want to consider that even though Novavax's pipeline is still young and predominantly unproven, the company is being valued at more than $1 billion in terms of overall value. It's quite possible that Novavax will continue to burn cash for the foreseeable future as it invests in new development programs and moves forward with its ongoing phase 1 and phase 2 studies. This doesn't necessarily mean the company won't succeed, but it does put downside pressure on a company that has historically produced losses and had a cumulative free-cash outflow of $279 million over the past decade.

It also wouldn't take much for Novavax to be knocked off its high horse if one of its primary studies in either RSV or influenza didn't meet its goals. I would personally guess that more than half of Novavax's current value is built into the success of its RSV and influenza platform, so a disappointment in either of these studies could seriously affect Novavax's share price.

One way or another, this has big-move potential, and risk-friendly investors should have this company on their watch lists.


White Mountains Insurance Group (NYSE: WTM)
The property and casualty reinsurance business is far from glamorous, but if a relatively conservative and nearly rock-steady investment exists within the sector, I would contend that White Mountains Insurance just might be it.

White Mountains is engaged in underwriting property and casualty insurance, as well as reinsuring products through the U.S. As you might imagine, this means that White Mountains can occasionally find itself at the mercy of Mother Nature. Events like Hurricane Sandy have a way of heavily impacting P&C insurers and reinsurers, and there's unfortunately very little these companies can do to predict when and where a natural disaster will strike.

However, one aspect that does work in favor of P&C insurers is that they possess the pricing power to boost premiums for existing customers on an as needed basis to ensure that they cover the catastrophe costs. The past year was incredibly kind to White Mountains, with very little in the way of catastrophe losses. Overall, this helped push the company's book value higher by 9.5% to $642 per share. With White Mountains operating out of four primary segments it noted significant strength from OneBeacon Insurance (NYSE: OB  ) , whose book value grew 17.3% and whose combined ratio (a measure of margin for insurers) came in at a steady 92% compared to this quarter last year.

If I could nitpick one aspect of White Mountains' generally conservative approach to running a business, it's that its dividend is far too conservative. At just $1 annually, yielding less than 0.2%, dividend-seeking investors had best consider looking elsewhere.

That aside, White Mountains is currently valued at around 10% of its book value, which, historically, makes this a good time to buy. Don't expect miraculous growth with a diversified insurance company, but do expect to sleep well at night. I'd suggest giving White Mountains a closer inspection.

Add these companies to your personalized Watch List to keep up on the latest news with each company:
• Add Novavax to My Watch List.
• Add Capstone Turbine to My Watch List.
• Add White Mountains Insurance Group to My Watch List.

Capstone isn't the only company set to profit from a booming energy market. These three stock have the potential to soar!